Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

ABSTRACT:

Purpose of review

The immunosuppressive agent cyclosporine was first reported to lower daily insulin dose and improve glycemic control in patients with new-onset type 1 diabetes (T1D) in 1984. While renal toxicity limited cyclosporine's extended use, this observation ignited collaborative efforts to identify immunotherapeutic agents capable of safely preserving β cells in patients with or at risk for T1D.

Recent findings

Advances in T1D prediction and early diagnosis, together with expanded knowledge of the disease mechanisms, have facilitated trials targeting specific immune cell subsets, autoantigens, and pathways. In addition, clinical responder and non-responder subsets have been defined through the use of metabolic and immunological readouts. Herein, we review emerging

SUBMITTER: Jacobsen LM 

PROVIDER: S-EPMC8053389 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature